PMID- 34511023
OWN - NLM
STAT- MEDLINE
DCOM- 20220113
LR  - 20220204
IS  - 2165-5987 (Electronic)
IS  - 2165-5979 (Print)
IS  - 2165-5979 (Linking)
VI  - 12
IP  - 1
DP  - 2021 Dec
TI  - Sevoflurane promotes the apoptosis of laryngeal squamous cell carcinoma in-vitro 
      and inhibits its malignant progression via miR-26a/FOXO1 axis.
PG  - 6364-6376
LID - 10.1080/21655979.2021.1962684 [doi]
AB  - Laryngeal squamous cell carcinoma (LSCC) is a laryngeal malignancy with a high 
      mortality rates, and its treatment remains difficult. Sevoflurane is a surgical 
      anesthesia which has anti-tumor effect. This investigation assessed the effects 
      of LSCC cells treatment with Sevoflurane in vitro and in vivo. Hep-2 and Tu177 
      cells, human LSCC samples and BALB/C nude mice were used for result assessments. 
      Cell viability, proliferation, migration and invasion were assessed via Cell 
      Count Kit-8, wound healing assay and transwell invasion assay respectively. 
      MiR-26a and FOXO1 expressions was examined by qRT-PCR. FOXO1, E-cadherin, 
      N-cadherin and vimentin activities were examined by Western blotting. Moreover, 
      animal experiments were performed to verify our findings in vitro. Lastly, 
      miR-26a and FOXO1 expression levels in clinical samples were analyzed. According 
      to the results, Sevoflurane decreased LSCC cells' viability and even stimulated 
      their apoptosis in vitro and in vivo. Moreover, it could reduce the migration, 
      invasion and EMT. Mechanistically, sevoflurane could downregulate miR-26a 
      expression and that miR-26a could negatively modulate FOXO1 activity. Thus, 
      sevoflurane could increase FOXO1 activity. In the clinical samples, miR-26a 
      expression was significantly upregulated, but FOXO1 was remarkably down-regulated 
      and miR-26a expression in LSCC was linked with better prognosis. In conclusion, 
      MiR-26a is increased and FOXO1 is reduced in human LSCC, Sevoflurane inhibits 
      proliferation and mediates apoptosis of LSCC cells. Further, MiR-26a binds FOXO1 
      directly, and FOXO1 expression is down-regulated by Sevoflurane. Finally, 
      Sevoflurane triggers LSCC cells apoptosis in vivo. Sevoflurane use to target 
      miR-26a/FOXO1 may be a novel alternative for LSCC therapy.
FAU - Liu, Dan
AU  - Liu D
AD  - Department Of Otorhinolaryngology, Huangshi Central Hospital Of Edong Healthcare 
      Group, Hubei Polytechnic University, Huangshi City, Hubei Province, China.
FAU - Wan, Lang
AU  - Wan L
AD  - Department Of Otorhinolaryngology, Huangshi Central Hospital Of Edong Healthcare 
      Group, Hubei Polytechnic University, Huangshi City, Hubei Province, China.
FAU - Gong, Hao
AU  - Gong H
AD  - Department Of Anesthesiology, Huangshi Maternity And Children's Health Hospital, 
      Huangshi City, Hubei Province, China.
FAU - Chen, Shiming
AU  - Chen S
AD  - Department Of Otolaryngology Head And Neck Surgery, Renmin Hospital Of Wuhan 
      University, Wuhan City, Hubei Province, China.
FAU - Kong, Yonggang
AU  - Kong Y
AD  - Department Of Otolaryngology Head And Neck Surgery, Renmin Hospital Of Wuhan 
      University, Wuhan City, Hubei Province, China.
FAU - Xiao, Bokui
AU  - Xiao B
AD  - Otorhinolaryngology-Head And Neck Surgery Laboratory, Wuhan University School Of 
      Medicine, Wuhan City, Hubei Province, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Bioengineered
JT  - Bioengineered
JID - 101581063
RN  - 0 (FOXO1 protein, human)
RN  - 0 (Forkhead Box Protein O1)
RN  - 0 (Foxo1 protein, mouse)
RN  - 0 (MIRN26A microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 38LVP0K73A (Sevoflurane)
SB  - IM
MH  - Animals
MH  - Apoptosis/*drug effects
MH  - Carcinoma, Squamous Cell/*metabolism
MH  - Cell Line, Tumor
MH  - Female
MH  - Forkhead Box Protein O1/genetics/metabolism
MH  - Humans
MH  - Laryngeal Neoplasms/*metabolism
MH  - Male
MH  - Mice
MH  - Mice, Nude
MH  - MicroRNAs/*genetics/metabolism
MH  - Middle Aged
MH  - Sevoflurane/*pharmacology
PMC - PMC8806578
OTO - NOTNLM
OT  - Sevoflurane
OT  - foxo1
OT  - laryngeal squamous cell carcinoma
OT  - miR-26a
COIS- No potential conflict of interest was reported by the author(s).
EDAT- 2021/09/14 06:00
MHDA- 2022/01/14 06:00
PMCR- 2021/09/13
CRDT- 2021/09/13 05:37
PHST- 2021/09/13 05:37 [entrez]
PHST- 2021/09/14 06:00 [pubmed]
PHST- 2022/01/14 06:00 [medline]
PHST- 2021/09/13 00:00 [pmc-release]
AID - 1962684 [pii]
AID - 10.1080/21655979.2021.1962684 [doi]
PST - ppublish
SO  - Bioengineered. 2021 Dec;12(1):6364-6376. doi: 10.1080/21655979.2021.1962684.